Leerink Partnrs Has Pessimistic View of ZNTL Q3 Earnings

Key Points

• Leerink Partners has revised down its Q3 2025 EPS estimate for Zentalis Pharmaceuticals to ($0.51) per share, down from a previous forecast of ($0.43).
• Zentalis Pharmaceuticals reported Q3 earnings of ($0.37) per share, which was better than analysts' consensus estimate of ($0.56).
• Current analyst ratings for Zentalis Pharmaceuticals include four "hold" ratings, two "buy" ratings, and one "strong buy" rating, with an average price target of $8.20.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at Leerink Partnrs lowered their Q3 2025 earnings estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, August 6th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.51) per share for the quarter, down from their previous estimate of ($0.43). The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals' Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($2.08) EPS, FY2026 earnings at ($1.88) EPS and FY2027 earnings at ($1.77) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.19.

A number of other equities analysts have also commented on the stock. Wells Fargo & Company decreased their price target on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. HC Wainwright raised shares of Zentalis Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 7th. Wedbush restated a "neutral" rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Finally, Wall Street Zen raised shares of Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Saturday, August 9th. Four analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.20.

Zentalis Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ:ZNTL traded up $0.01 during trading on Monday, reaching $1.50. The company had a trading volume of 334,757 shares, compared to its average volume of 1,232,247. The company has a fifty day moving average of $1.38 and a two-hundred day moving average of $1.54. The stock has a market capitalization of $107.84 million, a P/E ratio of -0.66 and a beta of 1.71. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $5.44.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ZNTL. Voya Investment Management LLC lifted its position in Zentalis Pharmaceuticals by 14.1% during the 4th quarter. Voya Investment Management LLC now owns 57,017 shares of the company's stock valued at $173,000 after acquiring an additional 7,058 shares during the period. Wells Fargo & Company MN lifted its position in Zentalis Pharmaceuticals by 26.8% during the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company's stock valued at $105,000 after acquiring an additional 7,305 shares during the period. Cerity Partners LLC lifted its position in Zentalis Pharmaceuticals by 58.7% during the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company's stock valued at $33,000 after acquiring an additional 7,579 shares during the period. Corton Capital Inc. purchased a new position in Zentalis Pharmaceuticals during the 4th quarter valued at about $32,000. Finally, State of Wyoming raised its holdings in Zentalis Pharmaceuticals by 30.1% in the first quarter. State of Wyoming now owns 45,176 shares of the company's stock worth $72,000 after buying an additional 10,460 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.